Soligenix, Inc. (SNGX)
$
1.22
Key metrics
Financial statements
Free cash flow per share
-2.2538
Market cap
12.3 Million
Price to sales ratio
0
Debt to equity
0.0507
Current ratio
3.1797
Income quality
0.8731
Average inventory
0
ROE
-2.6710
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases in the United States. The company reported a net loss of -$8,266,576.00 indicating challenges in its operations. In terms of core operations, the gross profit stands at -$119,371.00 which highlights the company's profitability from its main activities. The cost of revenue for the company is $119,371.00 showcasing its production and operational expenses associated with the development and commercialization of its products. Furthermore, the net income ratio is 0.00 reflecting the company's profitability margin and operational efficiency. Additionally, the net total of other income and expenses is $763,807.00 which provides insight into the organization’s non-core financial activities. Soligenix operates within two segments, Specialized BioTherapeutics and Public Health Solutions, developing innovative therapies such as SGX301 (HyBryte) for cutaneous T-cell lymphoma and SGX942 for inflammatory diseases, among others. Soligenix's stock is affordable at $2.69 making it an attractive option for budget-conscious investors. However, it has a low average trading volume of 178,611.00 indicating lower market activity, which could affect liquidity for potential investors. With a market capitalization of $12,305,079.00 the company is classified as a small-cap player, which often entails a different risk and growth profile compared to larger corporations. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape through its innovative therapies and public health solutions. Additionally, it belongs to the Healthcare sector, driving innovation and growth in the biopharmaceutical space, which plays a vital role in addressing unmet medical needs and advancing healthcare solutions.
Is Soligenix, Inc. (SNGX) a good investment?
Investing in Soligenix, Inc. (SNGX) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B-, with a Bullish outlook. Always conduct your own research before investing.
What is Soligenix, Inc. (SNGX)'s stock forecast?
Analysts predict Soligenix, Inc. stock to fluctuate between $1.02 (low) and $6.23 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Soligenix, Inc.'s market capitalization?
As of 2026-03-20, Soligenix, Inc.'s market cap is $12,305,079, based on 10,086,130 outstanding shares.
How does Soligenix, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Soligenix, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Soligenix, Inc. (SNGX) stock?
To buy Soligenix, Inc. (SNGX) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for SNGX. Place an order (Market, Limit, etc.).
What is the best time to invest in Soligenix, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Soligenix, Inc. stock ever split?
Soligenix, Inc.'s last stock split was 1:16 on 2024-06-06.
How did Soligenix, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$4.98 | Growth: -60.66%.
Where can I find Soligenix, Inc.'s investor relations reports?
Visit https://www.soligenix.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Soligenix, Inc.?
You can explore historical data from here
What is the all-time high and low for Soligenix, Inc. stock?
All-time high: $294.91 (2021-09-09) | All-time low: $1.02 (2026-02-05).
What are the key trends affecting Soligenix, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
prnewswire.com
PRINCETON, N.J., March 19, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that a summary of all the clinical trials completed to date evaluating HyBryte™ (synthetic hypericin) as a treatment for cutaneous T-cell lymphoma (CTCL) has been published in the peer-reviewed medical journal Expert Opinion on Investigational Drugs.
prnewswire.com
PRINCETON, N.J., March 10, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that SGX945 (dusquetide) has been granted Promising Innovative Medicine (PIM) designation in the United Kingdom (UK) by the Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of Behçet's Disease.
prnewswire.com
PRINCETON, N.J., Feb. 26, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) provided a positive recommendation on the Company's request for orphan drug designation for dusquetide (the active pharmaceutical ingredient in SGX945) for the treatment of Behçet's Disease, following review of the recently published Phase 2a clinical results demonstrating biological efficacy and safety in patients with Behçet's Disease.
prnewswire.com
PRINCETON, N.J., Feb. 24, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Christopher J.
prnewswire.com
PRINCETON, N.J., Feb. 12, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today issued an update letter from its President and Chief Executive Officer, Dr. Christopher J.
prnewswire.com
Study results support advancing SGX945 in this difficult-to-treat orphan disease Results suggest potential durability of response for maintenance therapy PRINCETON, N.J. , Dec. 18, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the results from its Phase 2a proof of concept study evaluating SGX945 (dusquetide) in the treatment of Behçet's Disease have been published in Rheumatology (Oxford), in an article entitled "Results from a Pilot Study of Dusquetide for the Treatment of Aphthous Ulcers Associated with Behçet Syndrome".
benzinga.com
Soligenix, Inc. (NASDAQ: SNGX) on Wednesday announced extended results of its ongoing Phase 2a trial of SGX302 (synthetic hypericin) for mild-to-moderate psoriasis.
prnewswire.com
Optimized Gel Formulation Demonstrates Clinical Success in Third Cohort of Patients PRINCETON, N.J. , Dec. 17, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today extended results of its ongoing Phase 2a trial of SGX302 (synthetic hypericin) for the treatment of mild-to-moderate psoriasis.
globenewswire.com
NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- via BioMedWire: — Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by BioMedWire ("BMW"), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork ), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.
prnewswire.com
50 of 80 patients enrolled in FLASH 2 study Blinded Response Rate to Date Exceeds Trial Estimate PRINCETON, N.J. , Nov. 19, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has completed the planned enrollment of 50 patients necessary for the interim analysis in its 80 patient confirmatory Phase 3 double-blind, placebo-controlled study evaluating HyBryte™ (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma (CTCL).
See all news
